Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02928497 · ClinicalTrials.gov registry record · NA
Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 481
- Enrollment target
NCT02928497: Completed NA study, sponsored by Boston Scientific Corporation.
NCT02928497 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 481 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02928497, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 481 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy to reduce the risk of stroke.
Primary Outcome
The primary safety endpoint is the 7-day combined rate of death, ischemic stroke, systemic embolism and complications requiring major cardiovascular or endovascular intervention measured only in the device arm, therefore the control is "0".
Interventions
- DEVICE WATCHMAN LAAC Device Implant
- DRUG Single Antiplatelet Therapy or No Therapy (Control)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 481 participants |
| Start Date | 2017-02-06 |
| Est. Completion | 2025-09-23 |
| Phase | NA |
What the finished NCT02928497 record still lists
NCT02928497 is an interventional study that assigns participants to a tested intervention. The registered 481 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 2 interventions - of which WATCHMAN LAAC Device Implant is the first listed.
NCT02928497 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02928497 about?
NCT02928497 is a clinical study titled "Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation". The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy to red...
What is the current status of trial NCT02928497?
This trial is currently completed. It is a NA study. The enrollment target is 481 participants. The study started on 2017-02-06. Estimated completion is 2025-09-23.
What interventions are being tested in trial NCT02928497?
The interventions under investigation include: WATCHMAN LAAC Device Implant (DEVICE), Single Antiplatelet Therapy or No Therapy (Control) (DRUG).
Who is sponsoring clinical trial NCT02928497?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02928497's enrollment target sits among peer trials
481 216th of 2000 higher than 1,785 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04449458 · 482 participants · NA
The Positively Quit Trial for Smoking Cessation
- NCT07079631 · 482 participants · Phase 1
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI